Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
Recombinant Fusion Proteins
Trebananib was well tolerated. Lack of response in the first stage of a Simon 2 stage design led to closure of this study. Prolonged PFS was observed in four pts, lasting 3.4-5.5 months.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency